Updated Systematic Review and Meta-Analysis of Randomized Controlled Trials: Antidepressants for Restricted and Repetitive Behaviors in Autism Spectrum Disorder
Prapinpatch Maneeton,Benchalak Maneeton,Yanisa Winichaikul,Suttipong Kawilapat,Nongluck Kienngam,Narong Maneeton
DOI: https://doi.org/10.2147/ndt.s465611
IF: 2.989
2024-10-02
Neuropsychiatric Disease and Treatment
Abstract:Prapinpatch Maneeton, 1 Benchalak Maneeton, 2 Yanisa Winichaikul, 3 Suttipong Kawilapat, 2 Nongluck Kienngam, 4 Narong Maneeton 2 1 Chiang Mai University Demonstration School, Faculty of Education, Chiang Mai University, Chiang Mai, Thailand; 2 Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 3 Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand; 4 Department of Education Psychology and Guidance Program, Faculty of Education, Chiang Mai University, Chiang Mai, Thailand Correspondence: Narong Maneeton, Department of Psychiatry, Faculty of Medicine, Chiang Mai University, 110 Intawaroros Road, Sriphum, Muang, Chiang Mai, 50200, Thailand, Tel +66 53 93 5422, Fax +66 53 5426, Email In previously randomized controlled trials (RCTs) on the efficacy of antidepressants in restricted and repetitive behaviors (RRBs) in autism spectrum disorder (ASD), outcomes overwhelmingly showed no benefits of antidepressants studied in the larger multisite RCTs over placebo. However, the positive effect of antidepressants in the RRBs found in the small preliminary studies requires confirmation in larger trials. We aimed to systematically review the efficacy of antidepressants in the treatment of RRBs in ASD by including RCTs from the SCOPUS, PubMed, Embase, Cochrane Controlled Trials Register, Clinical Trials.gov, and other databases in January 2024. Analyzing data from 609 participants across nine RCTs showed no significant difference in the overall pooled mean-end score for RRBs between antidepressant- and placebo-treated groups [SMD (95% CI) of − 0.25 (− 0.53, 0.02), I 2 = 54%, Tau 2 = 0.10, prediction interval = − 1.03, 0.53]. In small preliminary studies by one group, the clomipramine-treated group's pooled mean endpoint for obsessive-compulsive symptoms in ASD individuals showed a significantly better outcome than the desipramine-treated group, but in unconfirmed studies. Of the individual antidepressants investigated only clomipramine, and fluvoxamine illustrated some efficacy over placebo in small preliminary studies. These findings need confirmation in larger, multisite randomized controlled trials. There were no significant differences in the overall discontinuation rates or discontinuation due to adverse events between the antidepressant- and placebo-treated groups [RR (95% CI) of 1.30 (0.95, 1.78), I 2 = 0%, and 1.33 (0.71, 2.47), I 2 =0%, respectively]. Common side effects included agitation, appetite disturbance, anorexia, gastrointestinal issues, and sleep disturbance, with no significant differences between the antidepressant and placebo groups. In conclusion, the results regarding the efficacy of antidepressants in the treatment of RRBs in ASD are inconsistent. Since previous evidence found a correlation between attention-deficit hyperactivity disorder (ADHD) symptoms including overactivity and impulsivity, and RRBs, further trials including the use of non-stimulants such as atomoxetine could be conducted. Keywords: antidepressant, restricted and repetitive behavior, CY-BOCS, Y-BOCS, ASD Autism spectrum disorder (ASD), the early onset of a neurodevelopmental disorder, is characterized by deficits in social interaction and social communication and restrictive behavior, interest, or activity. 1 Although the prevalence of ASD varies between studies (ranging from 0.3 to 2.5%), 2–5 all evidence suggests that it is increasing worldwide. 2,4 Core symptoms of ASD tend to be lifelong disabilities, significantly affecting individuals, families, and society. 6 Restrictive and repetitive behaviors (RRBs), including repetitive motor movements and highly circumscribed interests, are one of the main symptoms of ASD, 1 frequently interfering with learning and social adaptation. The pathophysiology of RBBs is not adequately known. A previous study found that proactive control deficits in ASD can lead to difficulties in delaying responses and inappropriate behaviors, such as RRBs. 7 Another research study found that repetitive behaviors, impulsivity, and hyperactivity in intellectual disability overlap with ADHD. 8 This overlap has led to growing interest in the use of ADHD medications to manage ASD symptoms such as repetitive behaviors. The outcomes of one study suggest that ADHD medications, such as atomoxetine, 9 may be beneficial due to their effect on the norepinephrine transporter (NET). Comparison of the mechanisms of RRBs in ASD and obsessive-compulsive disorder (OCD) reveals distinct neurobiological and cognitive processes. In ASD, RRBs like hand-flapping, rocking, and insistence on sameness stem from sensory sensitivities, difficulty in adapting to -Abstract Truncated-
psychiatry,clinical neurology